JP2023538265A - ホスホイノシチド３－キナーゼ阻害剤の製剤 - Google Patents

ホスホイノシチド３－キナーゼ阻害剤の製剤 Download PDF

Info

Publication number
JP2023538265A
JP2023538265A JP2023507735A JP2023507735A JP2023538265A JP 2023538265 A JP2023538265 A JP 2023538265A JP 2023507735 A JP2023507735 A JP 2023507735A JP 2023507735 A JP2023507735 A JP 2023507735A JP 2023538265 A JP2023538265 A JP 2023538265A
Authority
JP
Japan
Prior art keywords
formulation
weight
amount
acid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538265A5 (https=
Inventor
カイドニーウス アーギス
ロッシ トーマス
エス．タン ホック
Original Assignee
ベンセラ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベンセラ，インコーポレイティド filed Critical ベンセラ，インコーポレイティド
Publication of JP2023538265A publication Critical patent/JP2023538265A/ja
Publication of JP2023538265A5 publication Critical patent/JP2023538265A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023507735A 2020-08-04 2021-08-03 ホスホイノシチド３－キナーゼ阻害剤の製剤 Pending JP2023538265A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063060843P 2020-08-04 2020-08-04
US202063060856P 2020-08-04 2020-08-04
US63/060,843 2020-08-04
US63/060,856 2020-08-04
PCT/US2021/044381 WO2022031729A1 (en) 2020-08-04 2021-08-03 Formulations of phosphoinositide 3-kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2023538265A true JP2023538265A (ja) 2023-09-07
JP2023538265A5 JP2023538265A5 (https=) 2024-08-13

Family

ID=77519798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507735A Pending JP2023538265A (ja) 2020-08-04 2021-08-03 ホスホイノシチド３－キナーゼ阻害剤の製剤

Country Status (6)

Country Link
US (1) US20220040193A1 (https=)
EP (1) EP4192431A1 (https=)
JP (1) JP2023538265A (https=)
CA (1) CA3187759A1 (https=)
TW (1) TWI886312B (https=)
WO (1) WO2022031729A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
JP2013539793A (ja) * 2010-10-13 2013-10-28 シェイプ ファーマシューティカルズ，インコーポレイテッド ヒストンデアセチラーゼ阻害薬のための医薬製剤
WO2020163525A1 (en) * 2019-02-06 2020-08-13 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CN102268014B (zh) * 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
US20170340649A1 (en) * 2016-05-30 2017-11-30 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
KR102358377B1 (ko) * 2016-12-28 2022-02-03 히사미쓰 세이야꾸 가부시키가이샤 첩부제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
JP2013539793A (ja) * 2010-10-13 2013-10-28 シェイプ ファーマシューティカルズ，インコーポレイテッド ヒストンデアセチラーゼ阻害薬のための医薬製剤
WO2020163525A1 (en) * 2019-02-06 2020-08-13 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）[ONLINE], JPN7024000076, ISSN: 0005651710 *

Also Published As

Publication number Publication date
TW202220662A (zh) 2022-06-01
CA3187759A1 (en) 2022-02-10
TWI886312B (zh) 2025-06-11
WO2022031729A1 (en) 2022-02-10
US20220040193A1 (en) 2022-02-10
EP4192431A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
US20250255872A1 (en) Topical formulation for jak inhibitor
EP4255442B1 (en) Jak inhibitor with a vitamin d analog for treatment of skin diseases
JP2025036464A (ja) 局所ホスホイノシチド３－キナーゼ阻害剤
TWI886312B (zh) 磷脂肌醇3-激酶抑制劑的調配物
US20230190755A1 (en) Topical formulations of PI3K-delta inhibitors
AU2022398467A1 (en) Formulations of pyrrolopyridine-aniline compounds
JP6625208B2 (ja) 経皮製剤
CN117157080A (zh) 用于治疗皮肤病的含维生素d类似物的jak抑制剂
US12310950B2 (en) Formulations of pyrrolopyridine-aniline compounds
US20260124160A1 (en) Pharmaceutical formulations of curcumin and/or resveratrol compounds
JP2003160489A (ja) オンダンセトロン経皮吸収用医薬組成物
EA052854B1 (ru) Композиция ингибитора jak для местного применения
HK1230920A1 (en) Topical formulation for a jak inhibitor
HK1182313B (en) Topical formulation for a jak inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260224